What is GLP-1 Therapy?

GLP-1 receptor agonist therapy has fundamentally shifted the landscape of weight management medicine. For the first time, patients who have struggled for years with diet and exercise alone now have access to medications that address the biological root causes of obesity — not just the symptoms.

If you have heard the names Ozempic, Wegovy, Mounjaro, or Zepbound in the news and wondered what they actually do — and whether they might be right for you — this guide offers a clear, clinically grounded explanation.

What Is GLP-1 and Why Does It Matter?

GLP-1 stands for glucagon-like peptide-1, a hormone produced naturally in the gut after eating. When food reaches the small intestine, GLP-1 is released and performs several critical functions:

• Signals the pancreas to release insulin in response to elevated blood sugar
• Suppresses glucagon (a hormone that raises blood sugar) from the pancreas
• Slows gastric emptying, making you feel full longer after meals
• Acts on the brain’s appetite centers to reduce hunger signals

In people with obesity or type 2 diabetes, this natural GLP-1 signaling system is often impaired. The gut produces less GLP-1 than it should, and the appetite regulation system becomes dysregulated — creating a physiological drive to overeat that willpower alone cannot overcome.^[1]

GLP-1 receptor agonist medications work by mimicking and amplifying this natural hormone signal — but at doses and durations far beyond what the body produces on its own.

The Two Medications: Semaglutide and Tirzepatide

Why Tirzepatide’s Dual Mechanism Matters

GIP is another incretin hormone, released alongside GLP-1 after meals. While its role is less well understood, GIP receptors are found in fat tissue, the brain, and the pancreas. Tirzepatide’s simultaneous activation of both GIP and GLP-1 receptors creates a synergistic effect that appears to produce greater weight loss than GLP-1 agonism alone — which the clinical trial data has confirmed decisively.^[2]

What the Clinical Trials Show

Semaglutide: The STEP Trials

The landmark STEP 1 trial, published in the New England Journal of Medicine in 2021, enrolled 1,961 adults with obesity. Participants who received semaglutide 2.4 mg weekly achieved a mean weight reduction of 14.9% of body weight at 68 weeks, compared to 2.4% with placebo. More than 86% of participants in the semaglutide group lost at least 5% of body weight.^[1]

Tirzepatide: The SURMOUNT-1 Trial

The SURMOUNT-1 trial, also published in the New England Journal of Medicine, compared three doses of tirzepatide against placebo in 2,539 adults with obesity. Participants on the highest dose (15 mg weekly) achieved a mean weight reduction of 22.5% of body weight at 72 weeks — with 57% of participants losing 20% or more of their body weight.^[2]

To put these numbers in context: prior to GLP-1 medications, the most effective non-surgical interventions for obesity rarely achieved more than 5–8% sustained weight loss. These medications represent a genuine step-change in what is medically achievable.

How GLP-1 Therapy Differs from Traditional Dieting

When people restrict calories through dieting alone, the body responds with powerful counter-regulatory mechanisms: increased hunger hormones, decreased satiety hormones, and metabolic adaptation that makes further weight loss progressively harder. This is not a failure of willpower — it is biology.^[3]

GLP-1 medications intervene at this biological level. They do not simply suppress appetite mechanically — they reset the hormonal conversation between the gut, pancreas, and brain that governs how the body relates to food. Patients on these medications consistently report that food “loses its pull” — the psychological preoccupation with eating that characterizes obesity-related hunger diminishes significantly.

FDA Approval and Safety Profile

Both medications carry FDA approval for chronic weight management:

• Wegovy (semaglutide 2.4 mg): Approved by the FDA in June 2021 for adults with BMI ≥30, or BMI ≥27 with at least one weight-related condition.^[4]
• Zepbound (tirzepatide 2.5–15 mg): Approved by the FDA in November 2023, with identical indication criteria.^[5]

The most common side effects for both medications are gastrointestinal — nausea, constipation, and diarrhea — and are typically dose-dependent, meaning they occur most frequently during dose escalation and improve as the body adjusts. Serious adverse events are uncommon but do exist; for this reason, physician evaluation and ongoing monitoring are essential for safe use.

Who Is a Good Candidate?

Clinical guidelines support GLP-1 therapy for adults who meet the following criteria:

• BMI of 30 or higher (obesity)
• BMI of 27 or higher with at least one weight-related comorbidity (e.g., type 2 diabetes, hypertension, sleep apnea, dyslipidemia)
• No personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2
• No prior pancreatitis
• Not pregnant or planning pregnancy

These criteria are evaluated at your initial consultation. Your physician will review your complete health history, current medications, and lab results before recommending a specific medication and starting dose.

What Physician Supervision Looks Like

GLP-1 medications require medical oversight — and that oversight is what separates a safe, effective program from a risky one. At Body Logic Health, every patient follows a structured clinical protocol:

1. Initial Consultation ($75): Comprehensive metabolic labs, biometric assessment, full health history review, and physician evaluation to determine candidacy and medication selection.
2. Dose Titration: Medications are started at low doses and escalated gradually based on tolerance and response — typically over 16–20 weeks.
3. Follow-Up Visits: Scheduled at weeks 4 and 12 to review vitals, measurements, progress, side effect management, and dosage adjustments.
4. Ongoing Monitoring: Labs are reviewed at key intervals to monitor liver function, kidney function, and metabolic markers.

Explore our program plans and pricing to understand the full care structure we offer.

The Bottom Line

GLP-1 receptor agonist therapy represents the most significant advance in obesity medicine in a generation. With clinical trial data showing 15–22% sustained body weight reduction, FDA approval for both semaglutide and tirzepatide, and a growing body of evidence on cardiovascular and metabolic benefits, these medications are no longer experimental — they are the new standard of care for eligible patients.

The key word is eligible. These medications require physician evaluation, ongoing supervision, and integration with lifestyle change to be safe and effective over the long term. At Body Logic Health, that is exactly what our program is built to deliver.

Learn more about our approach at bodylogic.health/about or explore frequently asked questions at bodylogic.health/faq.